EP0875253A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Chondroitinase compositions
Assignee: Seikagaku Corp
•
Filing: 1998-04-30
•
Granted: —
•
Expires: 2018-04-30
Abstract
Abstract This invention provides pharmaceutical compositions containing chondroitinase wherein a decrease in enzyme activity is very little even after long-term storage, and the pharmaceutical compositions are characterized in that they contain chondroitinase and a pharmaceutical carrier, and that an amount of reducing impurities per 1 g of said pharmaceutical carrier is 0.4 mL or less as a titer by a titration method with 0.01 N of ammonium ceric nitrate.
Inventors
- 👤 Shin-Ichi Ishikawa
- 👤 Mine Higuchi
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 22:12
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/06; A61K47/26; A61K38/00; A61K38/16; A61K38/43; A61K38/51; A61K47/08; A61K47/10; A61K9/00; A61K9/0012; A61K9/0019; A61P; A61P3/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
46 words
A pharmaceutical composition, characterized in
that it contain chondroitinase and a pharmaceutical
carrier, and that an amount of reducing impurities
contained in 1 g of said pharmaceutical carrier is 0.4
mL or less as a titer by a titration method with 0.01 N
ammonium ceric nitrate.
Claim 2
Dependent Claim
20 words
The pharmaceutical composition according to
claim 1, wherein a peroxide content in the pharmaceutical
carrier is 20 ppm or less.
Claim 3
Dependent Claim
39 words
The pharmaceutical composition according to
claim 1, wherein an amount of reducing impurities contained
in 1 g of the pharmaceutical carrier is 0.36 mL
or less as a titer by a titration method with 0.01 N
ammonium ceric nitrate.
Claim 4
Dependent Claim
16 words
The pharmaceutical composition according to
claim 1, wherein the pharmaceutical carrier is treated
with activated carbon.
Claim 5
Dependent Claim
16 words
The pharmaceutical composition according to
claim 1, wherein the pharmaceutical carrier is sucrose
and/or polyethylene glycol.
Claim 6
Dependent Claim
14 words
The pharmaceutical composition according to
claim 1, wherein the pharmaceutical carrier is polyethylene
glycol.
Claim 7
Dependent Claim
19 words
The pharmaceutical composition according to
claim 1, wherein the pharmaceutical carrier is a mixture
of sucrose and polyethylene glycol.
Claim 8
Dependent Claim
24 words
The pharmaceutical composition according to
claim 5, wherein the mixed ratio of polyethylene glycol
and sucrose is 0/1-10/1 by weight ratio of polyethylene
glycol/sucrose.
Claim 9
Dependent Claim
25 words
The pharmaceutical composition according to
claim 7, wherein the mixed ratio of polyethylene glycol
and sucrose is 2/1 by the weight ratio of polyethylene
glycol/sucrose.
Claim 10
Dependent Claim
19 words
The pharmaceutical composition according to
claim 5 or 6, wherein polyethylene glycol has an average
molecular weight of 3000-4000.
Claim 11
Dependent Claim
17 words
The pharmaceutical composition according to
claim 1, wherein the pharmaceutical carrier is polyoxyethylene
sorbitan fatty acid ester.
Claim 12
Dependent Claim
12 words
The pharmaceutical composition according to
claim 1, wherein chondroitinase is chondroitinase ABC.
Claim 13
Dependent Claim
19 words
The pharmaceutical composition according to
claim 1, wherein specific activity of chondroitinase ABC
is 300 U/mg protein or more.
Claim 14
Dependent Claim
14 words
The pharmaceutical composition according to
claim 1 in the form of a freeze-dried preparation,
Claim 15
Dependent Claim
18 words
An agent consisting of the pharmaceutical
composition according to claim 1 for the treatment of
intervertebral disc herniation.
Claim 16
Dependent Claim
32 words
A method for the treatment of mammals with
herniation, characterized in that an effective amount of
the pharmaceutical composition according to claim 1 is
injected into the intervertebral disc of the mammals.
Claim 17
Dependent Claim
15 words
Use of the pharmaceutical composition according
to claim 1 in the intervertebral disc dissolution
method.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.